Tempus AI (NASDAQ:TEM) Earns “Buy” Rating from BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $80.00 price target on the stock. BTIG Research‘s target price points to a potential upside of 18.33% from the stock’s current price.

A number of other research firms have also weighed in on TEM. Roth Capital started coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price on the stock. Guggenheim increased their price target on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, October 1st. The Goldman Sachs Group began coverage on Tempus AI in a research report on Monday, September 21st. They set a “neutral” rating and a $75.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Finally, Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $76.00 in a report on Tuesday, September 1st. Eleven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and a consensus target price of $72.47.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $67.61 on Monday. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a 50 day moving average price of $69.24 and a 200 day moving average price of $57.26. Tempus AI has a 52 week low of $40.77 and a 52 week high of $93.38. The firm has a market capitalization of $12.20 billion, a P/E ratio of -46.95 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The company’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) earnings per share. Sell-side analysts expect that Tempus AI will post -1.43 EPS for the current year.

Insider Buying and Selling at Tempus AI

In other news, Director Nadja West sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total value of $207,000.00. Following the transaction, the director directly owned 31,981 shares in the company, valued at approximately $2,206,689. This represents a 8.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the completion of the transaction, the chief executive officer owned 100,000 shares in the company, valued at approximately $7,747,000. This represents a 71.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,280,965 shares of company stock valued at $80,397,564. 24.26% of the stock is currently owned by company insiders.

Institutional Trading of Tempus AI

Institutional investors have recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC purchased a new stake in Tempus AI in the third quarter valued at approximately $27,000. EMC Capital Management acquired a new position in Tempus AI during the second quarter worth $29,000. Ulland Investment Advisors LLC acquired a new position in Tempus AI during the third quarter worth $41,000. Eastern Bank acquired a new position in Tempus AI during the third quarter worth $69,000. Finally, Whittier Trust Co. boosted its position in shares of Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after buying an additional 570 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.